IDH2 and glioblastoma: IDH-mutated tumors are associated with a favorable prognosis; non-1p/19q co-deletion tumors and primarily astrocytic gliomas are associated with a moderate prognosis; and IDH wild-type tumors and primarily WHO grade III or IV glioblastomas are associated with a poor prognosis (3).